Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• The androgen receptor (AR) is crucial for prostate cancer development and a primary therapeutic target.
• AR activation occurs via ligand binding to its C-terminal ligand-binding domain (LBD).
• Targeting AR is essential for managing all stages of prostate cancer.

Purpose of the Study:

• To investigate the role of the AR N-terminal domain (NTD) in prostate cancer progression.
• To evaluate the efficacy of AR NTD-based decoy molecules in inhibiting prostate cancer growth.
• To explore the mechanism by which AR NTD decoys affect cancer progression in castrated models.

Main Methods:

• Overexpression of AR NTD to create decoy molecules.
• Lentivirus delivery of decoys in castrated host models.
• Monitoring tumor volume doubling time and serum prostate-specific antigen (PSA) levels.
• Assessing the expression of androgen-regulated genes and AR interaction with androgen response elements.

Main Results:

• Decoy molecules significantly delayed hormonal progression in castrated hosts.
• Observed were increased tumor volume doubling times and prolonged time to reach pre-castrate PSA levels.
• Decoys reduced androgen-regulated gene expression and AR interaction with androgen response elements without affecting AR protein levels or nuclear localization.

Conclusions:

• The AR NTD plays a critical role in the hormonal progression of prostate cancer.
• AR NTD decoys show potential as a therapeutic strategy by interfering with AR function.
• This study supports the development of novel AR antagonists targeting the AR NTD for prostate cancer treatment.